$TG セラピューティクス(TGTX.US)$07:04 AM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M
$TG セラピューティクス(TGTX.US)$TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis TG Therapeutics Inc - Total Award Amount of Contract Has a Potential Value of $186.8 Mln
TG Therapeutics' low P/S ratio may be due to investor skepticism about its future revenue performance. The company's inferior revenue outlook compared to the industry is contributing to its low P/S ratio. Investors feel the potential for revenue improvement doesn't justify a higher P/S ratio.
$TG セラピューティクス(TGTX.US)$skyrocketed 28% after the biotech company reported better-than-expected net loss for fourth quarter and exceeded both the quarterly revenue and the outlook for 2024. The company said fourth quarter loss narrowed to 9 cents a share from 39 cents a year earlier. That's smaller than the 11 cents expected by analysts polled by Capital IQ, according to MT Newswires. Revenue for the three months ende...
The company's optimistic growth projection could delay profitability if not met. High debt levels necessitate stringent capital management, increasing investment risk in the loss-making company.
Insider selling at TG Therapeutics may indicate that insiders believe the shares are overpriced. High insider ownership aligns management's incentives with shareholders, but the selling warrants caution.
TG セラピューティクスに関するコメント
$AGBA グループ(AGBA.US)$
$TG セラピューティクス(TGTX.US)$
The company said fourth quarter loss narrowed to 9 cents a share from 39 cents a year earlier. That's smaller than the 11 cents expected by analysts polled by Capital IQ, according to MT Newswires.
Revenue for the three months ende...
まだコメントはありません